Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VQ-101 in GBA1-associated Parkinson's disease
2026-525848-15-00Phase 2Authorised
- Sponsor
- Vanqua Bio
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) and Parkinson's disease (GBA-PD) comparing VQ-101 with Placebo (2 arms). Primary endpoints: Time to clinically meaningful progression, Treatment-emergent adverse events and 2 more. Planned start Sep 2026; status: authorised.
02
Drugs
VQ-101
03
Conditions
Parkinson's disease (PD)Parkinson's disease (GBA-PD)
Beyond the preview
Go deeper on 2026-525848-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525848-15-00.